C.

human pharmaceuticals for the treatment of cardiovascular diseases, pulmonary diseases, pulmonary conditions, bronchoconstrictive diseases, bronchoconstrictive conditions, diseases and conditions associated with cardiac muscle dysfunction, cardiac muscle wasting, cardiac muscle atrophy, cardiac muscle weakness, infectious diseases,neurological diseases and conditions, neuromuscular diseases and conditions, musculoskeletal disorders, and diseases and conditions associated with skeletal muscle dysfunction, skeletal muscle wasting, skeletal muscle atrophy, skeletal muscle weakness, metabolic diseases and disorders, diabetes, hypertension, vascular diseases, and diseases and conditions associated with dysfunction of non-muscle myosin

research in the field of cellular assay screening and pharmaceutical discovery and development